Petros pharmaceuticals announces two upcoming fda meetings to review progress and path forward for stendra(r) (avanafil) rx-to-otc switch

Fda requests meeting to review the company's technology component and discuss further development and requirements new york, ny / accesswire / january 24, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces it has scheduled two meetings with the u.s. food and drug administration (fda) to review the company's progress and path forward in developing stendra as the first pde-5 inhibitor approved as an over-the-counter medication for erectile dysfunction. (please see important safety information below.
PTPI Ratings Summary
PTPI Quant Ranking